C

Contineum Therapeutics Inc
NASDAQ:CTNM

Watchlist Manager
Contineum Therapeutics Inc
NASDAQ:CTNM
Watchlist
Price: 12.57 USD 3.03% Market Closed
Market Cap: 366.8m USD

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Contineum Therapeutics Inc
NASDAQ:CTNM
356m USD
Loading...
IN
Aaswa Trading and Exports Ltd
BSE:512038
25.1T INR
Loading...
UK
Eight Capital Partners PLC
F:ECS
158.4B EUR
Loading...
US
GE Vernova LLC
NYSE:GEV
179.7B USD
Loading...
US
China Industrial Group Inc
OTC:CIND
121B USD
Loading...
NL
Nepi Rockcastle NV
JSE:NRP
89.3B ZAR
Loading...
US
Schlumberger NV
NYSE:SLB
73.5B USD
Loading...
US
Baker Hughes Co
NASDAQ:BKR
53.1B USD
Loading...
US
CoreWeave Inc
NASDAQ:CRWV
46.1B USD
Loading...
CH
Galderma Group AG
SIX:GALD
35.6B CHF
Loading...
IN
GTV Engineering Ltd
BSE:539479
4T INR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Contineum Therapeutics Inc
Glance View

Market Cap
366.8m USD
Industry
N/A

Contineum Therapeutics Inc is a US-based company operating in industry. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2024-04-05. Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The firm is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).

CTNM Intrinsic Value
7.02 USD
Overvaluation 44%
Intrinsic Value
Price
C
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top